CBD has reduced affinity for CB receptors. It functions as an antagonist or partial antagonist at endogenous cannabinoid receptors (equally CB1 and CB2 receptor varieties together with other G-protein-coupled receptors [GPCRs]) by inhibiting full binding of direct ligands, and will act principal